Mayo Clinic researchers have determined that chemotherapy can be safely delivered in the homes of patients across the U.S. [1].
This shift in delivery could significantly reduce the time cancer patients spend in hospital settings. By moving treatment from the clinic to the home, providers aim to lower the burden on patients and healthcare infrastructure while maintaining clinical safety [2].
A pilot study reported on March 27, 2026, demonstrated the feasibility of this model [3]. According to the research, the home-infusion model enabled the delivery of 93 IV chemotherapy infusions [4]. None of these infusions resulted in reactions or line infections [4].
Mayo Clinic researchers said chemotherapy can be safely delivered in patients' homes [1]. Other reports said patients received chemotherapy at home with no infusion reactions or infections [3].
To support the expansion of such home-care models, educational resources are being developed to guide patients and caregivers. Johns Hopkins Medicine produced a Spanish-language video tutorial specifically designed to instruct users on how to infuse chemotherapy at home [5]. The video serves as a practical tool to ensure that non-clinical settings meet the necessary safety standards for drug administration.
The transition to home-based care relies on a combination of rigorous patient screening and clear instructional guidance. The lack of adverse events in the Mayo Clinic cohort suggests that the risks associated with home administration are manageable when proper protocols are followed [3].
“Chemotherapy can be safely delivered in patients' homes.”
The validation of home-based chemotherapy represents a shift toward decentralized cancer care. By combining clinical evidence of safety from institutions like the Mayo Clinic with multilingual educational tools from Johns Hopkins Medicine, the healthcare system is addressing both the logistical and linguistic barriers that often hinder patient access to treatment.
